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Research article 
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Abstract Objectives. We evaluated platelet counts in end-stage renal disease and 
chronic viral hepatitis. 
Materials and Methods. We studied 70 patients with end-stage renal disease 
and chronic viral hepatitis and compared them to a control group of 45 patients 
without hepatitis.  
Results. The presence of viral hepatitis was associated with a higher 
prevalence of thrombocytopenia. Correlations between age, C-reactive protein, 
liver stiffness measurement, and platelet count were observed. C-reactive protein 
levels > 10 mg/dl were associated with a lower risk of thrombocytopenia in 
patients with end-stage renal disease and chronic viral hepatitis, yet age > 60 
years, dialysis vintage > 10 years, aspartate and alanine aminotransferase levels 
> 20 IU/L, albumin levels < 3.5 g/dl, and fibrosis stage ≥ 3 were not related. 
Conclusions. Chronic viral hepatitis leads to a higher prevalence of 
thrombocytopenia. Platelet counts in these patients begin to decrease 
significantly once liver fibrosis reaches stage III. 
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Highlights ✓ Thrombocytopenia is a common occurrence in patients with end-stage renal disease 
undergoing hemodialysis; 
✓ Chronic viral hepatitis B or C in end-stage renal disease patients does not impact platelet 
counts, suggesting that the natural course of liver disease is slowed in subjects undergoing 
hemodialysis 
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Introduction 
Thrombocytopenia (TCP) is defined as a platelet 
count below 150.000/mm3 and can be caused by a 
decrease in platelet production, increased destruction of 
platelets, or spleen sequestration. TCP is considered to 
be mild if the platelet count is above 70.000/mm3, and 
severe if below 20.000/mm3. Patients with a count 
above 50.000/mm3 are generally asymptomatic, but 
severe cases can present with spontaneous mucosal, 
intracranial, gastrointestinal, and genitourinary 
bleeding.  
End-stage renal disease (ESRD) is associated with 
abnormalities in both the number of platelets and their 
function. TCP etiology in ESRD is multiple and includes 
uremia, blood loss, sepsis, and heparin treatment. 
Hemodialysis (HD) in itself has been described as a 
cause of TCP since dialysis membranes have been 
shown to trigger platelet adhesion, aggregation, and 
activation. A thrombocyte count of 50,000 is the 
guideline threshold value for invasive dialysis access 
interventions and other surgical procedures (1, 2).  
Patients on HD also carry a greater risk of 
presenting with chronic hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infection, with a much higher 
prevalence in developing countries (3). TCP is one of 
the most widespread complications of chronic viral 
hepatitis (CVH). It appears secondary to hypersplenism 
in cirrhosis, immune-mediated mechanisms, shear 
stress, hyperfibrinolysis, bacterial translocation, sepsis, 
viral suppression of platelet production in the bone 
marrow, and decreased thrombopoietin. TCP interferes 
with interferon during antiviral treatment: therapy is not 
started if pre-treatment levels are lower than 
100.000/mm3; and at a platelet count under 25.000/mm3 
after initiation of treatment, therapy is discontinued (4). 
Currently recommended interferon-free treatment 
(grazoprevir and elbasvir) against HCV infection has a 
more favorable side-effect profile that does not impact 
platelet count (5). Although the challenge in the care of 
HCV patients with thrombocytopenia in initiating or 
maintaining IFN containing anti-viral therapy can be 
avoided with the use of Direct Antiviral Agents as the 
primary treatment modality, baseline thrombocytopenia 
has the potential of increasing the risk of drug cessation. 
Also, patients with baseline thrombocytopenia can 
exhibit compromised sustained virologic response 
(SVR) rates in comparison with those with acquired 
thrombocytopenia (6). Nucleoside analogues such as 
entecavir are the first line of treatment in chronic HBV 
infection; TCP is a very rare occurrence in patients 
undergoing this therapy (7). 
 
The natural history of CVH patients with ESRD is 
milder, usually asymptomatic compared with those 
affected only by CVH, presumably because of altered 
immunological response or a lower viral load in subjects 
on HD. Liver biopsy in ESRD patients, the gold standard 
for evaluating fibrosis, is generally avoided because of 
platelet dysfunctions and the important risk of 
hemorrhage (8, 9). 
The aim of the current study is to evaluate the 
platelet counts in ESRD and CVH compared to ESRD 
only, and determine correlations between TCP and 
clinical markers in both groups. 
Materials and Methods 
We performed a multicenter retrospective 
transversal study, which included 70 patients with 
ESRD and CVH (20 with HBV, 47 with HCV, and 3 
with HBV and HCV co-infection) and a control group 
of 45 patients with ESRD without CVH. The diagnosis 
of CVH was confirmed by the presence of the HBs 
antigen (Ag) or anti-HCV antibody (Ab) for more than 
6 months, with a viral load (HBV DNA, HCV RNA) 
detected by PCR greater than 50 IU/L. Patients in the 
control group were screened for viral hepatitis by 
confirming the absence of the HBs Ag and anti-HCV 
Ab. Patients in both groups had a diagnosis of ESRD and 
were on HD treatment. High-flux polysulfone dialyzer 
membranes were used for each patient. Only patients 
who gave informed consent were included in the study.  
We excluded comorbidities that can influence 
platelet count: aplastic anemia, bone marrow 
suppression by chemotherapy or irradiation, chronic 
alcohol abuse, congenital macrothrombocytopenia, 
human immunodeficiency virus co-infection, or 
antiviral treatment with interferon. Blood samples for 
determining alanine aminotransferase (ALAT), 
aspartate aminotransferase (ASAT), C-reactive protein 
(CRP), hyaluronic acid (HA), and lactate dehydrogenase 
(LDH) were taken at the start of HD sessions. Fibroscan 
measurements were made on the day the blood samples 
were taken, before HD, to determine the Metavir fibrosis 
stage (F). In HBV patients, the following liver fibrosis 
thresholds were used: 6 kPa to differentiate between 
F1/2, 9 kPa for F2/3, and 12 kPa for F3/4. In HCV 
patients, we used 7 kPa to differentiate between F1/F2, 
9.5 kPa for F2/3, and 12 kPa for F3/F4. For patients with 
HBV/HCV co-infection, the criteria for liver fibrosis in 
HCV infection were used (10). 
We compared the same variable in the two groups 
with Student’s t test to check for statistical significance 
between the different values when the distribution was 
normal, and the Mann-Whitney test when the 
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distribution was not normal. Mean values were 
presented with standard deviations (SD) and median 
values with interquartile ranges (IQR). The Shapiro-
Wilk test was used to verify whether data were normally 
distributed. The linear correlation between platelet count 
and different variables was verified by calculating 
Pearson’s correlation coefficient r. The Chi-square test 
and the Odds Ratio (OR) along with its 95% confidence 
interval (CI) were calculated to identify risk factors 
associated with TCP. Statistical analysis was carried out 
with the GraphPad Prism 6 software, version 6.01. 
Ethical approval. All procedures involving human 
participants were in accordance with ethical standards of 
institutional and national research committees and with 
the 1964 Helsinki Declaration and its later amendments 
or comparable ethical standards. 
Informed consent. Subjects’ participation in the 
study was voluntary, biological samples were collected 
after obtaining the written consent for participation. 
Results 
Table 1 presents the clinical characteristics of the 
two subject groups. The median age was 58.5 years 
(IQR = 47 - 68) for the group with ESRD and CVH and 
56 years (IQR= 48.5 - 67) for the control group (p = 
0.87). There were 24 men and 26 women in the CVH 
group, and 24 men and 21 women in the control group. 
 Platelet count between the two groups was not 
significantly different (mean of 168.316±65.570/mm3  
in the group with CVH vs. a mean of 179.068  
± 46.550/mm3 platelets in the control group,  
p = 0.46). Platelet count was also not different between 
patients with HBV and controls (p = 0.13), between 
patients with HCV and the control group (p = 0.72), and 
between patients with HCV and patients without HBV 
(p = 0.31). 
The dialysis vintage of patients with ESRD and 
CVH (mean of 137.6±83.95 months) was significantly 
higher (p = 0.004) than that of the control group (mean 
of 83.12±54.66 months). Patients in the group with 
ESRD and CVH had higher ALAT (p = 0.03), ASAT (p 
 
Table 1. Demographical and clinical differences between patients with 1ESRD and 2CVH vs patients with 
ESRD without CVH 
  ESRD with CVH ESRD without CVH p 
Number  70 45  
Age (years) Mean±8SD 55.66±14.75 57.64±14.17 0.581 
Sex (Male/Female) (%)  48% M vs 52%F 56% M vs 44%F  
Dialysis vintage  
(months) 
Median 124 79 0.006* 
25% 77 44.5  
 75% 186.25 123  
Kt/V Mean±SD 1.773±0.40 1.676±0.25 0.275 
Platelet count (103/mm3) Median 155 176 0.315 
 25% 118.5 158.5  
 75% 211.75 205.5  
3ALAT (IU/L) Median 17 15 0.033* 
 25% 13 10.5  
 75% 23.25 17.5  
4ASAT (IU/L) Median 15 11 0.006* 
 25% 11 7.5  
 75% 22.25 15  
Albumin (g/dL) Median 3.76 3.93 0.001* 
 25% 3.62 3.82  
 75% 3.91 4.23  
5CRP (mg/dL) Median 5.05 6 0.375 
 25% 1.975 2.65  
 75% 10.05 10.8  
6LDH (U/L) Median 269 284 0.448 
 25% 247.75 249  
 75% 303.5 324  
7HA (ng/dL) Median 55.61 45.44 0.249 
 25% 28.14 25.36  
 75% 97.04 66.72  
Fibroscan (kPa) Median 7.1 6.8 0.375 
 25% 5.57 5.05  
 75% 11.4 9.4  
1ESRD – end-stage renal disease; 2CVH – chronic viral hepatitis; 3ALAT – alanine aminotransferase; 4ASAT - 
aspartate aminotransferase; 5CRP - C-reactive protein; 6LDH - lactate dehydrogenase; 7HA - hyaluronic acid; 8SD 
– standard derivation         * p<0.05, significant value 
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= 0.006) values, and lower serum albumin concentration 
(p = 0.001) levels, although median values were in the 
normal range. No statistically significant difference was 
found in CRP, LDH, HA, and Fibroscan values between  
the two groups. Positive correlations were observed 
between platelet counts and age (r = 0.39, 95% CI = 0.13  
to 0.60, p = 0.004) and CRP (r = 0.35, 95% CI = 0.08 to 
0.57, p = 0.01), and negative correlations between 
Fibroscan values (r = -0.27, 95% CI = -0.51 to -0.001, p 
=0.04) and platelet count were observed in patients with 
ESRD and CVH (Table 2). In the control group, none of 
the variables correlated with platelet count (Table 3). 
 
Table 2. Correlation between platelet count and other variables in patients with aESRD and bCVH 
 Correlation  
coefficient  
95% cCI 
 interval 
r 
Age  0.39  0.13 to 0.60 0.004* 
Dialysis vintage -0.20 -0.45 to 0.07 0.15 
Albumin -0.13  -0.40 to 0.14 0.33 
dALAT -0.001 -0.28 to 0.27 0.99 
eASAT  0.002 -0.27 to 0.28 0.98 
fCRP  0.35  0.08 to 0.57 0.01* 
gLDH  0.06 -0.21 to 0.33 0.64 
hHA -0.27 -0.51 to -0.001 0.05 
Fibroscan -0.27 -0.51 to -0.001 0.04* 
aESRD – end-stage renal disease; bCVH – chronic viral hepatitis; cCI – confidence interval; dALAT – alanine 
aminotransferase; eASAT - aspartate aminotransferase; fCRP - C-reactive protein; gLDH – lactate 
dehydrogenase; hHA - hyaluronic acid;           * p<0.05, significant value. 
Table 3. Correlation between platelet count and other variables in the control group 
 Correlation 
coefficient 
   95% aCI 
interval 
  p 
Age -0.14 -0.51 to 0.26 0.47 
Dialysis vintage  -0.10 -0.47 to 0.30 0.62 
Albumin -0.09 -0.46 to 0.31 0.66 
bALAT -0.19 -0.54 to 0.21 0.35 
cASAT -0.19 -0.54 to 0.21 0.35 
dCRP  0.32 -0.08 to 0.63 0.11 
eLDH -0.25 -0.58 to 0.16 0.22 
fHA -0.39 -0.68 to 0.003 0.05 
Fibroscan -0.14 -0.5 to 0.26 0.49 
aCI – confidence interval; bALAT – alanine aminotransferase; cASAT - aspartate aminotransferase;  
dCRP - C-reactive protein; eLDH - lactate dehydrogenase; fHA - hyaluronic acid 
 
     The prevalence of TCP in our study was 44% (31 
subjects) in the group with ESRD and CVH (Figure 1), 
significantly higher (OR=3.14, 95% CI=1.01 to 9.7, 
p=0.04) than the 20% (9 subjects) in the control group 
(Figure 1). Univariate analysis showed that among the 
risk factors presented in Table 4, a CRP value higher than 
10 mg/dl was associated with fewer TCP cases in the 
group of subjects with CVH.  
    Liver fibrosis stage 3 was a risk factor for TCP. We 
found no significant difference in platelet count between 
F≥2 and F0-1 patients (p=0.25) or between F≥3 and F0-2 
patients (p=0.37) when F was evaluated by HA. We used 
80.24 ng/ml as the serum HA concentration for the F1/2 
threshold, and 88.54 ng/ml for F2/F3, values that we 
validated for the detection of liver fibrosis in a previous 
study (11). 
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Table 4. Different variables and their association with thrombocytopenia in patients with aESRD and bCVH 
 Odds Ratio 95% cCI p 
Age≥60 years 0.30 0.09 to 0.97 0.04* 
Dialysis time≥10 years 1.25 0.40 to 3.87 0.69 
Dialysis time≥15 years 0.93 0.26 to 3.26 0.91 
dALAT≥20(IU/L) 1.07 0.34 to 3.34 0.90 
eASAT≥20(IU/L) 1.42 0.43 to 4.71 0.55 
Albumin<3.5 g/dl 0.39 0.09 to 1.74 0.20 
fCRP≥10 mg/dl 0.18 0.03 to 0.93 0.02* 
gLDH≥225(U/L) 1.72 0.37 to 7.86 0.47 
hF2  2.85 0.88 to 9.19 0.07 
F3  3.83 1.06 to 13.8 0.03* 
iHA≥33.46 ng/ml (F0/F1) 1.88 0.53 to 6.67 0.31 
HA≥80.24 ng/ml (F1/F2) 2.07 0.62 to 6.93 0.23 
HA≥88.54 ng/ml (F2/F3) 1.71 0.50 to 5.80 0.38 
aESRD – end-stage renal disease; bCVH – chronic viral hepatitis; cCI – confidence interval; dALAT - 
alanine aminotransferase; eASAT - aspartate aminotransferase; fCRP - C-reactive protein; gLDH - 
lactate dehydrogenase; hF – fibrosis stage; iHA - hyaluronic acid;    * p<0.05, significant value. 
Discussions 
Although TCP prevalence was higher in patients 
with ESRD and CVH, we did not observe a statistically 
significant difference in platelet count between the two 
groups, because most patients had mild TCP with values 
above 100,000/mm3.  
This result is different from results reported by 
Nishida et al., which evidenced a significantly lower 
platelet count in patients on HD with CVH compared to 
subjects on HD alone (159.000 ±53.000/mm3vs 
193.000±73.000/mm3, p<0.001) (12).  
A significantly lower platelet count (p<0.01) in 
patients on HD with HCV (145.300±38.300/mm3) 
compared to patients on HD without HCV 
(174.900± 50.600/mm3) was also reported by Ando et 
al. Their study also found that megakaryocytopoiesis 
showed a time-dependent reduction in patients on HD, 
and peripheral destruction and sequestration in patients 
with HCV infection contributed to the etiology of TCP 
(13).  
The dialysis process by itself could influence 
platelet count: Ahmed et al. found a lower platelet count 
in the blood samples taken 15 minutes after HD started 
compared to the ones taken before HD, both in the 
ESRD group and in the ESRD and CVH group. This 
change in platelet count, although statistically 
significant, was not considered clinically important (14). 
Bat et al. observed an increase in absolute immature 
platelet number, immature platelet fraction, and 
increased thrombopoietin levels three hours after the HD 
session. Complement activation during HD leads to 
immediate platelet consumption and release of 
immature platelets from the bone marrow (15).  
A longer dialysis vintage is a risk factor for 
infection with HBV and HCV (3). A dialysis vintage 
longer than 10 years is associated with higher 
cardiovascular disease as well as infection-related and 
all-cause mortality (16). In our study, patients with CVH 
had a longer dialysis vintage than control patients, but a 
dialysis vintage longer than 10 years was not a TCP risk 
factor.  
We found ALAT and ASAT to be higher in the 
ESRD and chronic hepatitis group. Nishida et al. also 
found this significant difference in ALAT and ASAT 
levels and concluded that ALAT over 20 IU/L was 
significantly associated with TCP in patients with HCV 
infection and ESRD (12). In contrast, Ahmed et al. 
found no significant difference regarding ALAT and 
ASAT values (14). Aminotransferases have been 
observed to be lower in patients undergoing HD and 
peritoneal dialysis. Increases of 15-35% in their levels 
after HD have been attributed to hemoconcentration. 
Patients with ESRD and CVH have higher 
aminotransferase levels than those with ESRD alone, 
but lower values than patients with CVH without ESRD. 
Factors hypothesized to be responsible for this decrease 
in aminotransferases are hemodilution, the reduction of 
viremia after the dialysis procedure, increased 
production of hepatocyte growth factor (and accelerated 
liver regeneration), an increase in α-interferon 
production after HD, and activation of CD69+ 
lymphocytes (17). 
Fluid retention, especially before HD, is a cause for 
hemodilution-related hypoalbuminemia (18). Kubrusly 
et al. found a significant increase in albumin levels post-
HD compared to pre-HD (19). In patients with CVH, 
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albumin is a marker of liver function and its protein 
synthesis, and is significantly decreased in cirrhosis 
compared to lower liver fibrosis stages. A positive 
correlation was observed between platelet count and 
albumin by Osada et al. (r=0.59, p<0.001) (20) and 
Zucker et al. (p=0.38, p<0.01) (21). In patients with 
HCV infection alone, a 0.5 g/dl decrease in albumin 
concentration was associated with a 33% increase in the 
relative risk of TCP (p<0.005). In our study, albumin 
levels approached the lower part of the reference range 
for both groups and as expected, patients with CVH and 
ESRD had lower albumin concentration compared with 
the control group. We observed no correlation between 
albumin and platelet count. A serum albumin 
concentration lower than 3.5 g/dl was not associated 
with a risk for TCP. This result can be explained by the 
weaker impact on liver function that viral infection has 
in patients undergoing HD.  
We found a positive correlation between platelet 
count and CRP; and a CRP level higher than 10 mg/dl 
was associated with a lower risk of TCP in patients with 
ESRD and CVH, explained by thrombocytosis that is 
secondary to inflammatory processes (22). Elevated 
CRP in patients on HD is a known occurrence and is 
associated with cardiovascular disease mortality and all-
cause mortality (23). Coated platelets are a subgroup of 
platelets activated by thrombin and collagen; these 
express high levels of surface procoagulant proteins. 
Valayodon et al. studied them in patients with ESRD 
and reported that patients with a 40% or higher 
proportion of coated platelets had higher CRP levels 
than other ESRD patients, but no significant difference 
between the total platelet counts (24).  
LDH is known to be elevated in patients on HD, 
increased by 20%-40% in patients with ESRD compared 
to normal volunteers (25). LDH concentrations in both 
of our groups were above the reference range in our 
study, but no particular relationship with platelet counts 
was established. 
In viral hepatitis, liver biopsy is the gold standard 
method to assess fibrosis staging, but it carries with it 
risks such as hemorrhage, haemobilia, and gallbladder 
and colonic perforation. ESRD patients have a greater 
bleeding risk because of the platelet dysfunction and 
underlying coagulopathy, and the use of heparin for the 
dialysis procedure. Among non-invasive methods for 
determining liver fibrosis, elastography has been proven 
to be valuable in investigating diffuse liver diseases, has 
a particularly high accuracy in detecting liver cirrhosis 
(84% sensitivity and 94% specificity in HCV infection, 
75% sensitivity and 90% specificity in HBV infection), 
and has reduced the need for liver biopsies (26, 27). The 
withdrawal of fluid during HD influences liver stiffness 
measurement results, even in patients without viral 
hepatitis infection. Kellner et al. showed that a 
significant increase in liver stiffness measurement was 
found after HD in patients with an initial level lower 
than 7.1 kPa (28). In our study, for patients with chronic 
viral hepatitis, F3 stage liver fibrosis was a risk factor 
for TCP. 
Serum HA is a biomarker that has been proven 
useful in distinguishing between various fibrosis stages. 
In a previous study, we detected cut-off values for 
hyaluronic acid that can differentiate between F0/1 
(33.46 ng/ml), F1/2 (80.24 ng/ml) and F2/3 (88.54 
ng/ml), but none of the F stages determined by HA could 
be associated with a risk for TCP in our patients (11, 29).  
Because this was a retrospective study, other factors 
that influence platelet count, such as splenomegaly, 
could not be assessed. The small sample size of patients 
with cirrhosis did not allow us to properly measure the 
impact of several factors on patients with F4. Liver 
fibrosis was only detected by non-invasive methods 
since liver biopsy was not performed because of the high 
risk for hemorrhage. 
 
Conclusions 
TCP is a common occurrence in patients with 
ESRD undergoing HD. The overlap with chronic 
hepatitis increases its prevalence even more among this 
particular group of patients. We found that CVH in 
ESRD patients does not impact platelet counts, 
suggesting that the natural course of liver disease slows 
down in subjects undergoing HD. In these patients, once 
liver fibrosis reaches F3, they are at a risk for TCP. 
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